An immune cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR gamma-delta T cells) for advanced solid tumors that have not responded to standard treatments. The therapy uses donor cells that are specially trained to find and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has come back or not responded to at least two standard treatments.
- Your tumor must test positive for two markers called PD-L1 and HLA-G.
- You have at least one measurable tumor on a scan (CT or MRI).
- Your blood counts, kidney, and liver function meet study requirements.
- You have not had certain transplants, gene therapies, or active infections recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This early-phase trial tests a new type of cell therapy using donor immune cells (called CAR-γδT cells) that are engineered to attack a protein called B7H3 found on many solid tumors. The goal is to see if this treatment is safe and could help people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.